
    
      AZ201801 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group
      study carried out in 2 sequentially overlapping cohorts evaluating the safety, efficacy and
      tolerability of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland
      Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
    
  